scholarly journals Characteristics Associated with Participation in ENGAGED 2 – A Web-based Breast Cancer Risk Communication and Decision Support Trial

2020 ◽  
Vol 24 (5) ◽  
Author(s):  
Karen Wernli
Keyword(s):  
Breast Cancer ◽  
Decision Support ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Communication ◽  
Web Based

scholarly journals iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management

2016 ◽  
Vol 156 (1) ◽  
pp. 171-182 ◽  
Author(s):  
Ian M. Collins ◽  
Adrian Bickerstaffe ◽  
Thilina Ranaweera ◽  
Sanjaya Maddumarachchi ◽  
Louise Keogh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Decision Support Tool ◽  
Cancer Risk Assessment ◽  
Web Based ◽  
Support Tool ◽  
Breast Cancer Risk Assessment ◽  
Risk Assessment And Management

Resisting Good News: Reactions to Breast Cancer Risk Communication

2006 ◽  
Vol 19 (2) ◽  
pp. 115-123 ◽  
Author(s):  
Amanda J. Dillard ◽  
Kevin D. McCaul ◽  
Pamela D. Kelso ◽  
William M. P. Klein
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Communication ◽  
Good News

scholarly journals Breast cancer risk communication: Assessment of primary care physicians by standardized patients

2009 ◽  
Vol 11 (10) ◽  
pp. 735-741 ◽  
Author(s):  
Julie O Culver ◽  
Deborah J Bowen ◽  
Susan E Reynolds ◽  
Linda E Pinsky ◽  
Nancy Press ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Communication ◽  
Primary Care Physicians ◽  
Standardized Patients ◽  
Communication Assessment

Implementing decision support for breast cancer chemoprevention in primary care.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13038-e13038 ◽  
Author(s):  
Jersen Telfort ◽  
Meghna S. Trivedi ◽  
Hae Seung Yi ◽  
Hilary Colbeth ◽  
Alejandro Vanegas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Decision Support ◽  
High Risk ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Primary Care Providers ◽  
Categorical Variables ◽  
High Risk Women ◽  
Before And After

e13038 Background: Breast cancer risk assessment and chemoprevention with anti-estrogens among high-risk women are underutilized. We developed web-based decision support tools for high-risk women, RealRisks, and their primary care providers (PCPs), BNAV, which are integrated into clinic workflow. Methods: We conducted a pilot study in 50 women who were found to have a 5-year risk of invasive breast cancer ≥1.67% according to the Gail model during screening mammography. RealRisks includes modules on breast cancer risk and chemoprevention, as well as interactive games to communicate risk and preference elicitation for chemoprevention. A tailored patient and provider action plan is generated summarizing their breast cancer risk profile. Before and after interacting with RealRisks, participants completed validated questionnaires on breast cancer and chemoprevention knowledge and chemoprevention intention. Prior to their next clinic visit, their PCPs were given access to the BNAV reference toolbox. High-risk referrals and chemoprevention uptake were assessed by medical chart review. Paired t-tests and chi-square tests were used to analyze continuous and categorical variables pre/post-intervention, respectively. Results: From Mar to Aug 2016, 50 high-risk women were enrolled and 40 were evaluable. Median age 64.5 years (range, 49-72); white/black/Hispanic (%): 37.5/25/37.5; 35% had adequate health literacy; median 5-year breast cancer risk was 2.2% (range, 1.7-3.9). Before and after interacting with RealRisks, we observed an increase in adequate breast cancer knowledge (60% vs. 84%, p = .01) and chemoprevention knowledge (5% vs. 25%, p < .01). After viewing RealRisks, 30% of women were interested in taking an anti-estrogen for chemoprevention, 33% not interested, and 37% unsure. Thus far, only 2 were referred for high-risk consultations and no high-risk women initiated chemoprevention. Conclusions: Despite increased interest in chemoprevention after exposure to RealRisks, additional barriers to chemoprevention uptake exist, including competing comorbidities and time constraints during the clinical encounter. Targeting younger women with higher breast cancer risk may increase chemoprevention uptake. Clinical trial information: NCT02954900.

Sign in / Sign up

Export Citation Format

Share Document